X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1735) 1735
Book Review (204) 204
Publication (123) 123
Book Chapter (2) 2
Conference Proceeding (2) 2
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1654) 1654
humans (1092) 1092
animals (868) 868
male (864) 864
pyrrolidines - pharmacokinetics (696) 696
pyrrolidines - pharmacology (587) 587
female (510) 510
pharmacology & pharmacy (484) 484
rats (479) 479
adult (348) 348
middle aged (319) 319
pyrrolidines - chemistry (307) 307
pyrrolidines - therapeutic use (301) 301
pyrrolidines - administration & dosage (257) 257
mice (256) 256
chemistry, medicinal (227) 227
pharmacokinetics (227) 227
dose-response relationship, drug (218) 218
administration, oral (197) 197
neurosciences (192) 192
aged (190) 190
structure-activity relationship (188) 188
pyrrolidines - metabolism (165) 165
rats, sprague-dawley (165) 165
pyrrolidines - adverse effects (157) 157
brain - metabolism (149) 149
pyrrolidines - chemical synthesis (149) 149
benzamides - pharmacokinetics (144) 144
pyrrolidines - blood (140) 140
adamantane - analogs & derivatives (135) 135
chemistry, organic (130) 130
receptors, dopamine d2 - metabolism (126) 126
analysis (121) 121
biochemistry & molecular biology (120) 120
treatment outcome (111) 111
tissue distribution (108) 108
time factors (107) 107
kinetics (105) 105
brain - diagnostic imaging (104) 104
dogs (103) 103
diabetes mellitus, type 2 - drug therapy (100) 100
double-blind method (98) 98
pyrrolidines (97) 97
molecular structure (91) 91
biological availability (89) 89
brain (88) 88
stereoisomerism (88) 88
drugs (87) 87
abridged index medicus (86) 86
toxicology (86) 86
tomography, emission-computed, single-photon (83) 83
rats, wistar (82) 82
in-vivo (77) 77
dopamine (76) 76
drug therapy (76) 76
vildagliptin (76) 76
half-life (74) 74
psychiatry (74) 74
adolescent (72) 72
corpus striatum - metabolism (72) 72
type 2 diabetes (72) 72
area under curve (70) 70
endocrinology & metabolism (70) 70
reproducibility of results (70) 70
research (70) 70
pharmacology/toxicology (69) 69
rat (69) 69
young adult (69) 69
double-blind (68) 68
glucagon-like peptide-1 (68) 68
medicine & public health (68) 68
binding (67) 67
in-vitro (67) 67
radiopharmaceuticals - pharmacokinetics (67) 67
chromatography, high pressure liquid (66) 66
drug interactions (66) 66
potent (66) 66
article (65) 65
chemistry, analytical (65) 65
clinical neurology (65) 65
metabolism (65) 65
in vitro techniques (64) 64
radiology, nuclear medicine & medical imaging (64) 64
disease models, animal (62) 62
drug design (62) 62
nitriles - pharmacokinetics (62) 62
oncology (62) 62
pharmacology (62) 62
protein binding (62) 62
adamantane - therapeutic use (60) 60
corpus striatum - diagnostic imaging (60) 60
care and treatment (59) 59
positron emission tomography (59) 59
models, molecular (58) 58
receptor (58) 58
adamantane - pharmacokinetics (57) 57
metabolites (57) 57
expression (56) 56
nitriles - pharmacology (56) 56
brain - drug effects (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1708) 1708
German (11) 11
Japanese (8) 8
Chinese (4) 4
French (4) 4
Spanish (3) 3
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Psychiatry, ISSN 0002-953X, 08/2008, Volume 165, Issue 8, pp. 988 - 995
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 2, pp. 153 - 157
Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs. We examined... 
pharmacokinetics | dipeptidyl peptidase-4 inhibitor | glucagon-like peptide-1 receptor agonist | target molecular binding occupancy | pharmacodynamics | Dipeptidyl peptidase-4 inhibitor | Pharmacodynamics | Pharmacokinetics | Glucagon-like peptide-1 receptor agonist | Target molecular binding occupancy | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOLOGY & PHARMACY | PROMOTES SATIETY | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Peptides - pharmacokinetics | Nitriles - pharmacokinetics | Peptides - administration & dosage | Peptides - metabolism | Hypoglycemic Agents - administration & dosage | Pyrrolidines - metabolism | Adamantane - therapeutic use | Adamantane - administration & dosage | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Piperidines - metabolism | Pyrrolidines - pharmacokinetics | Adamantane - metabolism | Models, Molecular | Uracil - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Liraglutide - therapeutic use | Venoms - therapeutic use | Ligands | Venoms - metabolism | Sitagliptin Phosphate - pharmacokinetics | Venoms - pharmacokinetics | Nitriles - therapeutic use | Liraglutide - metabolism | Sitagliptin Phosphate - metabolism | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Molecular Targeted Therapy | Pyrrolidines - therapeutic use | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Liraglutide - pharmacokinetics | Uracil - administration & dosage | Venoms - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - metabolism | Piperidines - pharmacokinetics | Adamantane - pharmacokinetics | Nitriles - metabolism | Reproducibility of Results | Diabetes Mellitus, Type 2 - blood | Algorithms | Piperidines - therapeutic use | Sitagliptin Phosphate - therapeutic use | Uracil - metabolism | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Uracil - pharmacokinetics | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - therapeutic use | Uracil - analogs & derivatives | Binding | Drugs | Effectiveness | Peptidase | Glucagon | Diabetes mellitus | Theoretical analysis | Low level | Receptors | Inhibitors | Nitric oxide | Occupancy | Hemoglobin | Agonists | Glucagon-like peptide 1 | Drug dosages | Index Medicus
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2011, Volume 72, Issue 2, pp. 235 - 246
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: This study provides antimuscarinic agents for overactive bladder (OAB) display variable association with side effects... 
blood−brain barrier | fesoterodine | pharmacokinetics | CNS | overactive bladder | antimuscarinic | Antimuscarinic | Overactive bladder | Blood-brain barrier | Fesoterodine | Pharmacokinetics | blood-brain barrier | COGNITIVE IMPAIRMENT | TROSPIUM CHLORIDE | BLOOD-BRAIN-BARRIER | RECEPTOR ANTAGONIST | P-GLYCOPROTEIN | OLDER PATIENTS | ANTICHOLINERGIC DRUGS | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | HEALTHY-VOLUNTEERS | BINDING | Mandelic Acids - pharmacokinetics | Humans | Solifenacin Succinate | Male | Receptors, Muscarinic - metabolism | Chromatography, High Pressure Liquid | Benzofurans - pharmacokinetics | Brain - metabolism | Tandem Mass Spectrometry | Urinary Bladder, Overactive - drug therapy | Tolterodine Tartrate | Muscarinic Antagonists - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics | Cell Line | Pyrrolidines - pharmacokinetics | Rats | Rats, Sprague-Dawley | Blood-Brain Barrier - metabolism | Randomized Controlled Trials as Topic | Animals | Tetrahydroisoquinolines - pharmacokinetics | ATP Binding Cassette Transporter, Sub-Family B - metabolism | Cresols - pharmacokinetics | Phenylpropanolamine - pharmacokinetics | Quinuclidines - pharmacokinetics | Urinary incontinence | Analysis | Oxybutynin | Permeability | Drug therapy | Blood proteins | Protein binding | Brain | Acetylcholine receptors (muscarinic) | Central nervous system | Membrane permeability | Clinical trials | Data processing | Cerebrospinal fluid | Plasma proteins | Side effects | Urinary bladder | P-Glycoprotein | Geriatrics | Index Medicus | Uropharmacology Themed Section
Journal Article
1990, ISBN 9518805008, 1 v. (various pagings).
Book
Journal Article
Journal of Pharmacy and Pharmaceutical Sciences, ISSN 1482-1826, 09/2015, Volume 18, Issue 3, pp. 434 - 447
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 01/2008, Volume 48, Issue 1, pp. 85 - 95
We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction... 
Type 2 diabetes | Angiotensin converting enzyme inhibitor | Calcium channel blocker | Dipeptidyl peptidase IV inhibitor | Vildagliptin | Angiotensin receptor blocker | Pharmacokinetics | LAF237 | RISK | angiotensin receptor blocker | PHARMACODYNAMICS | BLOOD-PRESSURE | DIABETES-MELLITUS | BIOTRANSFORMATION | type 2 diabetes | vildagliptin | calcium channel blocker | angiotensin converting enzyme inhibitor | MEN | pharmacokinetics | PHARMACOLOGY & PHARMACY | HYPERTENSION | TYPE-2 | STAGE RENAL-DISEASE | dipeptidyl peptidase IV inhibitor | Nausea - chemically induced | Tablets | Humans | Middle Aged | Half-Life | Pyrrolidines - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Nitriles - pharmacokinetics | Ramipril - administration & dosage | Drug Interactions | Tetrazoles - administration & dosage | Ramipril - analogs & derivatives | Adamantane - administration & dosage | Ramipril - adverse effects | Amlodipine - administration & dosage | Adamantane - analogs & derivatives | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Administration, Oral | Pyrrolidines - pharmacokinetics | Amlodipine - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Cross-Over Studies | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Valine - adverse effects | Nitriles - adverse effects | Tetrazoles - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - adverse effects | Valsartan | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Antihypertensive Agents - administration & dosage | Pyrrolidines - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics | Valine - administration & dosage | Nitriles - administration & dosage | Amlodipine - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Headache - chemically induced | Adamantane - pharmacokinetics | Adamantane - adverse effects | Valine - pharmacokinetics | Valine - analogs & derivatives | Ramipril - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Tetrazoles - adverse effects | Amlodipine | Dosage and administration | Enzyme inhibitors | Research | Index Medicus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2012, Volume 52, Issue 10, pp. 1494 - 1505
Dipeptidyl peptidase-4 (DPP-4) inhibition is a well- characterized treatment for type 2 diabetes mellitus (T2DM). The objective of this model-based... 
PK/PD | pharmacodynamics | DPP-4 | drug development | meta-analysis | Pharmacokinetics | diabetes | CLINICAL DRUG DEVELOPMENT | METFORMIN | RECEPTOR OCCUPANCY | TRIAL | IMPROVES GLYCEMIC CONTROL | IV INHIBITOR | DOUBLE-BLIND | EARLY DECISION-MAKING | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | Triazoles - administration & dosage | Dipeptides - pharmacokinetics | Glycated Hemoglobin A - metabolism | Humans | Pyrazines - administration & dosage | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Nitriles - pharmacokinetics | Nitriles - administration & dosage | Uracil - administration & dosage | Piperidines - pharmacokinetics | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - pharmacokinetics | Adamantane - analogs & derivatives | Biomarkers - metabolism | Hypoglycemic Agents - therapeutic use | Piperidines - administration & dosage | Pyrrolidines - pharmacokinetics | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptides - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Models, Biological | Pyrazines - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Uracil - pharmacokinetics | Uracil - analogs & derivatives | Type 2 diabetes | Patient outcomes | Hypoglycemic agents | Dosage and administration | Models | Research | Drug therapy | Drug dosages | Index Medicus
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 05/2016, Volume 107, Issue 5, pp. 659 - 665
TAS ‐102, a novel oral antitumor agent, consists of trifluridine and tipiracil hydrochloride (molar ratio, 1:0.5). We investigated the effects of food on... 
pharmacokinetics | Effect of food | 102 | tipiracil hydrochloride | trifluridine | TAS | TAS-102 | Tipiracil hydrochloride | Trifluridine | Pharmacokinetics | VIVO | 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE | ANTITUMOR-ACTIVITY | CANCER | TRIAL | ONCOLOGY | FLUORINATED PYRIMIDINES | DEOXYRIBONUCLEIC ACID | THYMIDINE PHOSPHORYLASE | Neoplasms - metabolism | Thymine - pharmacokinetics | Nausea - chemically induced | Area Under Curve | Humans | Middle Aged | Pyrrolidines - adverse effects | Biological Availability | Male | Antineoplastic Agents - therapeutic use | Trifluridine - pharmacokinetics | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Uracil - pharmacology | Antineoplastic Agents - adverse effects | Leukopenia - chemically induced | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Thymine - pharmacology | Neutropenia - chemically induced | Trifluridine - pharmacology | Fasting | Thymine - therapeutic use | Thymine - adverse effects | Pyrrolidines - pharmacokinetics | Food-Drug Interactions | Japan | Anemia - chemically induced | Uracil - therapeutic use | Neoplasms - drug therapy | Cross-Over Studies | Trifluridine - therapeutic use | Asian Continental Ancestry Group | Uracil - adverse effects | Trifluridine - adverse effects | Aged | Neoplasms - pathology | Uracil - pharmacokinetics | Drug Combinations | Uracil - analogs & derivatives |